Piper Sandler Reiterates a Buy Rating on AbCellera Biologics (ABCL)

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the best biotech penny stocks to buy right now. On July 28, Piper Sandler analyst Allison Bratzel maintained a Buy rating on AbCellera Biologics Inc. (NASDAQ:ABCL) and set a price target of $17.00.

Is AbCellera Biologics Inc. (ABCL) the Best Canadian Penny Stock to Invest in Now?

A research team analyzing data on a computer screen, uncovering details about the antibody discovery platform.

AbCellera Biologics Inc. (NASDAQ:ABCL) generated $4.2 million in total revenue in fiscal Q1 2025, and reported a net loss of $45.6 million, compared to a net loss of $40.6 million in 2024.

The company reached a cumulative total of 97 partner-initiated programs starts with downstreams, and maintained a cumulative total of 16 molecules to have reached the clinic.

AbCellera Biologics (NASDAQ:ABCL) solves antibody discovery problems by integrating data science, technology, infrastructure, and interdisciplinary teams. It develops and discovers antibody medicines for indications across therapeutic areas, including metabolic and endocrine conditions, cancer, and autoimmune disorders.

It boasts technology platforms that unlock drug classes, modalities, and targets, including T-cell engagers, peptide-MHCs, and transmembrane proteins.

While we acknowledge the potential of ABCL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABCL and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.